VITRAKVI Maintains Market Leadership Across the 7MM Amid Growing TRK Inhibitor Competition | DelveInsight
DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...
DelveInsight Business Research, LLP: VITRAKVI Maintains Market Leadership Across the 7MM Amid Growing TRK Inhibitor Competition | DelveInsight
VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...
eLife3d
Tissue inflammation induced by constitutively active STING is mediated by enhanced TNF signaling
This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for ...
Targeted Oncology5d
Understanding the Significance of ESR1 Mutations in Breast Cancer
Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...